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WT1 and its transcriptional cofactor BASP1 redirect the differentiation
pathway of an established blood cell line
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Stefan G. E. ROBERTS*†2
*Faculty of Life Sciences, The Michael Smith Building, University of Manchester, Oxford Road, Manchester M13 9PT, U.K., and †Department of Biological Sciences, University at
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The Wilms’ tumour suppressor WT1 (Wilms’ tumour 1) is a
transcriptionalregulatorthatplaysacentralroleinorganogenesis,
and is mutated or aberrantly expressed in several childhood and
adult malignancies. We previously identiﬁed BASP1 (brain
acid-soluble protein 1) as a WT1 cofactor that suppresses the
transcriptional activation function of WT1. In the present study
we have analysed the dynamic between WT1 and BASP1 in the
regulation of gene expression in myelogenous leukaemia K562
cells. Our ﬁndings reveal that BASP1 is a signiﬁcant regulator
of WT1 that is recruited to WT1-binding sites and suppresses
WT1-mediated transcriptional activation at several WT1 target
genes.WeﬁndthatWT1andBASP1candivertthedifferentiation
programme of K562 cells to a non-blood cell type following
induction by the phorbol ester PMA. WT1 and BASP1 co-
operate to induce the differentiation of K562 cells to a neuronal-
like morphology that exhibits extensive arborization, and the
expression of several genes involved in neurite outgrowth and
synapse formation. Functional analysis revealed the relevance of
the transcriptional reprogramming and morphological changes,
in that the cells elicited a response to the neurotransmitter ATP.
Taken together, the results of the present study reveal that WT1
andBASP1candivertthelineagepotentialofanestablishedblood
cell line towards a cell with neuronal characteristics.
Key words: brain acid-soluble protein 1 (BASP1), K562 cell,
Wilms’ tumour, Wilms’ tumour 1 (WT1).
INTRODUCTION
The Wilms’ tumour suppressor protein WT1 (Wilms’ tumour 1)
is mutated or aberrantly expressed in several childhood and adult
cancers,whereitcanactaseitheratumoursuppressororoncogene
[1,2]. WT1 is a transcriptional regulator that plays a central role
in the development of several organs and tissues, including the
kidneys,gonadsandspleen[3].Morerecentstudieshaverevealed
a critical role for WT1 in the development of speciﬁc neuronal
tissues including the retinal ganglia and olfactory epithelia [4,5].
Indeed, WT1 is also expressed in the spinal cord and speciﬁc
regions of the brain during development [6].
WT1 can either activate or repress genes involved in growth,
apoptosis and differentiation. The transcriptional regulatory
activity of WT1 is subject to extensive control by interaction with
other factors that can act as either co-activators or co-repressors
[7]. We identiﬁed BASP1 (brain acid-soluble protein 1) as a
WT1-interacting protein that binds to the suppression domain of
WT1 (residues 71–101) and inhibits its transcriptional activation
function [8,9]. WT1 and BASP1 are spatially and temporally co-
expressed at several sites in the developing embryo, suggesting a
signiﬁcant role for BASP1 in the regulation of WT1 activity in
development. The suppression domain of WT1 also forms a key
binding site for the serine protease HtrA2, which cleaves WT1
under apoptotic conditions [10].
BASP1 was originally isolated from neuronal cells, where it
is predominantly cytoplasmic with partial membrane localization
mediated by the N-terminal myristoylation of BASP1 [11]. The
functionofBASP1inneuronalcellsisstillunclear,butithasbeen
proposed to play a role in nerve sprouting. Several cell types also
contain a nuclear pool of BASP1 [9,12,13]. Indeed BASP1
contains a bipartite NLS (nuclear localization sequence), sites
of SUMO (small ubiquitin-related modiﬁer)-modiﬁcation, and a
portion of BASP1 localizes to PML (promyelocytic leukaemia)
bodies within the nucleus [13].
Since our previous report of a transcriptional role for BASP1
[9], others have also described a function for BASP1 in the nu-
cleus. It has been reported that BASP1 localizes from the
nucleus to the cytoplasm in cells that are undergoing apoptosis
[12]. In addition, a recent study found that BASP1 can inhibit
cellular transformation by the v-Myc oncogene, and can block
the regulation of Myc target genes [14]. This same work showed
that BASP1 is consistently down-regulated in Myc-transformed
cells. BASP1 does not interact with Myc, however, suggesting
an indirect mechanism. BASP1 is also down-regulated in a
signiﬁcant proportion of hepatocellular carcinomas, and this
is attributed to silencing of the BASP1 gene by methylation
[15]. In addition, BASP1 expression has also been reported to
be frequently down-regulated in both ALL (acute lymphocytic
leukaemia) and CLL (chronic lymphocytic leukaemia) [16,17].
Abbreviations used: ALL, acute lymphocytic leukaemia; BASP1, brain acid-soluble protein 1; ChIP, chromatin immunoprecipitation; CLL, chronic
lymphocytic leukaemia; CPA, cyclopiazonic acid; DAB2, Disabled homologue 2; ENC1, ectodermal neural cortex 1; FBS, foetal bovine serum; fura 2/AM,
fura 2 acetoxymethyl ester; GFP, green ﬂuorescent protein; HA, haemagglutinin; ITGA2, integrin α2; ITGA2B, integrin α2b; ITGB3, integrin β3; MAOA,
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The array data are available in a MIAME-compliant standard in the Array Express database (Experiment E-MEXP-2573, http://www.ebi.ac.uk/
microarray-as/ae/).
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Taken together, these recent studies suggest that BASP1 probably
acts as a tumour suppressor.
The role of WT1 in leukaemia has attracted considerable
attention over the last few years [2,18,19]. In total, 74% of
AML (acute myeloid leukaemia), 66% of ALL and over 50%
of CLL samples show high levels of wild-type WT1 expression.
Moreover, leukaemia patients with elevated WT1 have a poor
prognosis and signiﬁcantly reduced 5-year survival rates. WT1
plays a role in haemopoeisis, serving to maintain the self-
renewal of primitive CD34
+ cells in the bone marrow [18].
As differentiation proceeds WT1 is down-regulated and is not
expressed in mature blood cells. Thus it has been proposed
that, in leukaemia, WT1 contributes to the maintenance of the
dedifferentiated state and promotes proliferation [2].
In the present study, we have analysed the role of BASP1
as a WT1 cofactor in myelogenous leukaemia K562 cells. We
ﬁnd that BASP1 regulates WT1 activity at several previously
identiﬁed WT1 target genes and that this involves the recruitment
of BASP1 to the promoter. WT1 and BASP1 together divert
the differentiation of K562 cells away from the blood cell
lineage and direct differentiation towards cells with neuronal-like
morphology, gene expression pattern and functional properties.
The results of the present study suggest that the WT1/BASP1
dynamic plays a central role in directing cell fate during
differentiation.
EXPERIMENTAL
Cell culture and transfection
K562 cells were cultured in RPMI 1640 medium supplemented
with 10% FBS (foetal bovine serum), 100 mg/ml streptomycin,
100 units/ml penicillin and 2 mM L-glutamine. Cells were
transfected using Lipofectamine
TM 2000 (Invitrogen) or by
electroporation using the Amaxa Nucleofector. K562 cells stably
transfected with pcDNA3 were selected with 2 mg/ml G418
(Sigma) and pools of cells were maintained in 2 mg/ml
G418. PMA and haemin were purchased from Sigma. Control
siRNAs (small interfering RNAs) used were from Ambion
(AM4611 and AM4635) and WT1 siRNAs were from Santa Cruz
Biotechnology (sc-36846) and Ambion (s14912).
Cell extracts
To prepare whole-cell extracts, cells were washed twice in ice-
cold PBS and then lysed for 20 min in Triton lysis buffer
[20 mM Tris/HCl (pH 7.4), 137 mM NaCl, 2 mM EDTA, 25 mM
2-glycerophosphate, 1 mM sodium orthovanadate, 1 mM PMSF,
1×protease inhibitor cocktail (Sigma), 10% (v/v) glycerol and
1% (v/v) Triton X-100]. Insoluble material was removed by
centrifugation at 16000 g for 10 min at 4◦C. FLAG-tagged
BASP1 was immunoprecipitated from whole-cell extracts using
anti-FLAG M2 afﬁnity gel (Sigma). Nuclear and cytosolic
extracts were prepared using a nuclear extract kit (Active Motif)
according to the manufacturer’s protocol. For immunoblotting,
equal amounts of protein were resuspended in protein loading
dye, resolved by SDS/PAGE and then transferred on to a PVDF
membrane.
Antibodies and immunoﬂuorescence
Anti-WT1 (C-19), anti-lamin A/C (N-18), anti-P2X5 (H-90)
and anti-DAB2 (Disabled homologue 2) (H-110) were from
Santa Cruz Biotechnology. Anti-pol II (RNA polymerase II)
(ab5408), anti-ENC1 (ectodermal neural cortex 1) (ab56348)
Table 1 Primers used for mRNA analysis
AREG, gene encoding amphiregulin; EGFR, epidermal growth factor receptor; GAPDH,
glyceraldehyde-3-phosphate dehydrogenase.
Gene Forward (5 →3 ) Reverse (5 →3 )
GAPDH ACAGTCAGCCGCATCTTCTT ACGACCAAATCCGTTGACTC
Renin GAAAGCCTGAAGGAACGA GTACTGGGTGTCCATGTAGTT
AREG TGGATTGGACCTCAATGACA ACTGTGGTCCCCAGAAAATG
Angiopoietin GCAAATGTGCCCTCATGTTA TAGATTGGAGGGGCCACA
Bax GCCCTTTTGCTTCAGGGTTT TCCAATGTCCAGCCCATGAT
EGFR GTGACCGTTTGGGAGTTGATGA GGCTGAGGGAGGCGTTCTC
ETS-1 AAACTTGCTACCATCCCGTACGT ATGGTGAGAGTCGGCTTGAGAT
p21 GCAGACCAGCATGACAGATTT GCAGACCAGCATGACAGATTT
VDR CTGACCCTGGAGACTTTGAC GGATTAGGGCTTCCTCTTGGA
ITGA2 AACTCTTTGGATTTGCGTGTG TGGCAGTCTCAGAATAGGCTTC
DAB2 GGGCATTTGGTTACGTGTG CTTTGCTGGCTTCCTCTATC
ITGA2B AGGTGAGAGGGAGCAGAACA TCCACCTTGAGAGGGTTGAC
ITGB3 GTGACCTGAAGGAGAATCTGC TTCTTCGAATCATCTGGCC
ENC1 CCCCACAATCAACAAATGG ACTACTGCGGCGTTGCTAA
MAOA CCTTGACTGCCAAGATTCACTTC TGCACTTAATGACAGCTCCCAT
Synapsin I GAACACATGCAAGGAGCTGA AGAGCACCAGGTTCAGGAAG
P2X5 TCTTTGCCTGGTGCCCGTTG ATCACGGAGCCCAGTCGGAAG
γ-Globin GGACAAGGCTACTATCACAA CAGTGGTATCTGGAGGACAG
and anti-β-tubulin (ab6046) were from Abcam. Control IgG and
anti-WT1 (6F-H2) antibodies were from Millipore. The
rabbit anti-FLAG antibody was from Cell Signaling Technology.
Anti-BASP1 antibodies have been described previously [9,13].
Immunoﬂuorescence was performed as described previously [9]
using Jackson ImmunoResearch Dylight secondary antibodies.
Plasmids and reagents
To generate pcDNA3-FLAG-HA (control vector) (HA is
haemagglutinin), the following oligonucleotides were annealed
and subcloned into the EcoRI/XbaI sites of pcDNA3: sense
5
 -AATTCGTCGACAAGACTACAAGGACGACGATGACAA-
GTCGGCCGCTGGAGGATACCCCTACGACGTGCCCGACT-
ACGCCTAGT-3
  and antisense 5
 -CTAGACTAGGCGTAGTCG-
GGCACGTCGTAGGGGTATCCTCCAGCGGCCGACTTGTC-
ATCGTCGTCCTTGTAGTCTTGTCGACG-3
 .H u m a nBASP1
cDNA was ampliﬁed (using 5
 -GCGGATCCATGGGAGGC-
AAGCTCAGC-3
  and 5
 -CCGAATTCCCTCTTTCACGGTTA-
CGGT-3
 ) and subcloned into the BamHI/EcoRI sites of the
control vector to give the expression construct pcDNA3-BASP1-
FLAG-HA. The plasmid for GFP (green ﬂuorescent protein)
expression was pCMV6-AC-GFP (Origene).
ChIP (chromatin immunoprecipitation) and RNA analysis
Total RNA was prepared using the Qiagen RNeasy kit and cDNA
prepared using the Promega Reverse Transcription kit or the Bio-
Rad cDNA synthesis kit. Real-time PCR was performed using a
Bio-Rad MiniOpticon System and SYBR Green assay reagents.
Primers for mRNA analysis are shown in Table 1.
ChIP assays were performed as described previously [20].
Primers for the ampliﬁcation of WT1-binding regions were
designedbasedontheworkofothers:renin[21],VDR(vitaminD
receptor) [22], ETS-1 [23] and amphiregulin [23,24]. Sequences
of the primers are shown in Table 2. Control primers ampliﬁed a
region 3
  of the human c-Myc gene.
Affymetrix microarray and analysis
Stably transfected V-K562 and B-K562 cells were seeded
at equal densities (approx. 1×10
5 cells/ml) in RPMI 1640
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Table 2 Primers used for ChIP analysis
AREG, gene encoding amphiregulin.
Gene Forward (5 →3 ) Reverse (5 →3 )
Renin GCTTAACCTCCTAGGTCTTG GTGGAGGAAGTCTGTAAATC
VDR CACCTGGCTCAGGCGTCC GCCAGGAGCTCCGTTGGC
ETS-1 CCTAAAGAGGAGGGGAGAGC AGGGGAAGTTGGCACTTTG
AREG TTTAAGTTCCACTTCCTCTCA GGTGTGCGAACGTCTGTA
c-Myc AGAACTGCTAAACCAGAATGT AGACAGGGTCTCACCATCT
medium supplemented with 10% FBS, 100 mg/ml streptomycin,
100 units/ml penicillin and 2 mM L-glutamine. After 24 h,
total RNA was extracted or cells were treated with 100 nM
PMA for a further 48 h to induce differentiation prior to
RNA extraction. RNA was isolated using the Qiagen RNeasy
kit then treated with DNase I (Roche) prior to analysis
by microarray. For each condition, microarray analysis was
performed on three independently prepared RNA samples.
Affymetrix microarray analysis was performed using the human
genome U133 Plus 2.0 array, following the manufacturer’s
guidelines and results were submitted in a MIAME-compliant
standard to the Array Express database (Experiment E-MEXP-
2573, http://www.ebi.ac.uk/microarray-as/ae/).
Technical quality control was performed with dChip
(V2005) (http://www.dchip.org; [26]) using the default
settings. Background correction, quantile normalization and
gene expression analysis were performed using GCRMA
in Bioconductor [27]. Differential expression analysis was
performed using Limma using the functions lmFit and eBayes
[28]. Gene lists of differentially expressed genes were controlled
for FDR (false discovery rate) errors using the method of
QVALUE [29].
Where RNA expression was studied from vehicle or PMA-
treated V-K562 or B-K562 cells (independently prepared
triplicates), a list of signiﬁcant gene expression changes was
generatedbyﬁlteringfortheANOVAinteraction(q-value<0.05)
and fold change between differentiated B-K562 compared with
V-K562>+ −2. This gave a genelist of 788 probesets. This set
was segregated into ﬁve clusters based on similarity of expression
proﬁle across the dataset with a k-means clustering algorithm
using a Manhattan distance metric. Clustering was performed
on the means of each sample group (log 2) that had been
z-transformed (for each probe set the mean was set to 0, and the
S.D. was set to 1). k-means clustering was performed on
the basis of similarity of proﬁles across the dataset using the ‘Su-
perGrouper’plugin ofmaxdViewsoftware (availablefromhttp://
bioinf.man.ac.uk/microarray/maxd/). Each cluster from k-means
clustering was sorted further by hierarchical clustering.
Functional annotation of the genes was performed using
DAVID version 2 (http://david.niaid.nih.gov/david/version2/
index.htm).
Calcium imaging
PMA-treatedV-K562orB-K562cellswerewashedwithTyrode’s
solution [140 mM NaCl, 5 mM KCl, 1 mM MgCl2, 3 mM CaCl2,
10 mM Hepes, 10 mM glucose and 1 mM pyruvic acid (pH 7.4)]
for 5 min and then loaded with 2 μM fura 2/AM (fura 2
acetoxymethyl ester; Molecular Probes, Invitrogen) containing
thenon-ionicdispersingagentPluronicF-127(MolecularProbes,
Invitrogen) for 40 min. Loaded cells were visualized using an
Olympus IX71 microscope with a 40× oil-immersion lens,
and images were captured using a SensiCam QE camera
(Cooke Corporation). Excitation wavelengths of 340 nm and
380 nm were used with an emission wavelength of 510 nm.
Images were collected every 4 s using Imaging Workbench
5.2 (Indec Biosystems). During experiments, cells were kept
under constant perfusion with Tyrode’s solution followed by
alternating changes in solutions. All solutions were applied to
the bath using a gravity ﬂow perfusion system (AutoMate Scien-
tiﬁc) and laminar ﬂow perfusion chambers (RC-25F, Warner
Scientiﬁc). Imaging data were collected as a ratio of ﬂuorescence
intensities. All ﬂuorescence values were calibrated using the
fura 2/AM Calcium Imaging Calibration kit (Invitrogen). The
effective dissociation constant Kd was calculated to be 250 nM
and calcium concentrations were determined using the formula
outlined in [30]. An evoked response was deﬁned as an increase
inﬂuorescencethatwasgreaterthan2S.D.valuesabovebaseline.
Data were graphed without any ﬁltering using OriginPro 7.5
software.StatisticalcomparisonsweremadeusingaFisher’sexact
test (http://www.langsrud.com/stat/index.html) with the limit of
signiﬁcance set at P<0.05. Cells were stimulated with either
50 mM KCl, 10 mM ATP (Sigma) or 10 mM CPA (cyclopiazonic
acid; Sigma).
RESULTS
A cell-line model system to study WT1/BASP1 function
Our previous work found that K562 cells, which are derived
from a myelogenous leukaemia, express WT1 but do not express
detectable BASP1 [9]. Indeed, in these cells WT1 elicited
transactivation that could be repressed by the transient expression
of BASP1. We therefore generated a stable K562 cell-line
derivative that expresses BASP1. The BASP1-coding region was
cloned into the pcDNA3 vector in-frame with tandem FLAG and
HA epitope tags fused to the C-terminus of BASP1. pCDNA3-
BASP1-FLAG-HA or a control empty pcDNA3-FLAG-HA
vector were transfected into K562 cells and cultured in the
presence of G418 to select cells that express the neomycin-
resistance gene, which is also located on the pCDNA3 plasmid.
Following selection, the cells were used to prepare nuclear
and cytoplasmic extracts, and the samples were immunoblotted
with anti-WT1 or anti-BASP1 antibodies (Figure 1A). WT1 was
expressedinboththevector-derivedandBASP1-expressingK562
cells (designated V-K562 and B-K562 respectively) and was
primarily present in the nuclear fractions. BASP1 was located
in both the nucleus and cytoplasm of the B-K562 cells, but was
not expressed in the V-K562 cells. To conﬁrm the efﬁciency of
the nuclear/cytoplasmic fractionation, immunoblots were also
performed to detect lamin A/C and β-tubulin as nuclear and
cytoplasmic markers respectively.
We next prepared whole-cell extracts from V-K562 and B-
K562cells,andsubjectedthemtoimmunoprecipitationwithanti-
FLAG antibodies to purify BASP1. The precipitates were then
immunoblotted with either anti-WT1 or anti-BASP1 antibodies
(Figure1B).Consistentwithourpreviousstudies,theendogenous
WT1 in B-K562 cells co-immunoprecipitated with anti-FLAG
antibodies only with extracts prepared from B-K562 cells [8].
Asmentionedabove,WT1canactasanoncogeneinleukaemic
cells, whereas BASP1 is associated with tumour suppressor
activity. We therefore monitored the duplication rate of V-K562
and B-K562 cells over a period of 4 days and plotted the results
as average fold increase in cell number (Figure 1C). The B-K562
cells proliferated at a small, but signiﬁcantly lower, rate than the
V-K562 cells, suggesting that BASP1 suppresses the growth of
K562 cells.
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Figure 1 Characterization of a K562 cell-line derivative that expresses BASP1
(A) V-K562 and B-K562 cells were used to prepare nuclear (N) and cytoplasmic (C) extracts and immunoblotting was performed with the antibodies indicated. (B) Anti-FLAG antibodies were used
in immunoprecipitation (IP) with nuclear extracts prepared from V-K562 and B-K562 cells. The samples were then immunoblotted with anti-WT1 or anti-BASP1 antibodies. (C) An equal number of
V-K562 and B-K562 cells were grown over a 4 day period and each day the cells were counted. The y-axis of the graph shows the fold increase in cell number during the period. Immunoblots
of WT1, BASP1 and β-tubulin are shown in the right-hand panels. Values are means+ −S.D. for six independent experiments. P <0.01 by Student’s t test.
The regulation of transcription by WT1 and BASP1 in K562 cells
We next performed an Affymetrix expression array with mRNA
derived from V-K562 and B-K562 cells. The data are presented
as a volcano plot in Figure 2(A). The grey area of the plot
indicates small changes with low signiﬁcance, whereas the red
area indicates signiﬁcant changes (q-value<0.1). In total, 1308
genes were up-regulated and 1376 genes were down-regulated in
theB-K562cellscomparedwiththeV-K562cells(1706and1683
probesets respectively; full details are in Supplementary Table S1
at http://www.BiochemJ.org/bj/435/bj4350113add.htm). Genes
previously described as WT1 targets are highlighted in blue
in Figure 2(A) (full details are in Supplementary Table S2 at
http://www.BiochemJ.org/bj/435/bj4350113add.htm). In the set
of differentially expressed genes with q-value <0.1, the WT1
target genes showed signiﬁcant down-regulation (19 genes were
repressed, compared with three that showed increased activity,
Fisher’s exact test P= 0.006). Thus, while the overall expression
changes caused by BASP1 included a similar number of up- and
down-regulated genes, 19 out of the 22 WT1 target genes on the
array that exhibited altered expression in the presence of BASP1
were transcriptionally repressed.
The efﬁcacy of the array data was conﬁrmed by the direct
measurement of several WT1 target genes by qPCR (quantitative
PCR) (Figure 2B). Bax was included as a control because its
expression did not signiﬁcantly change in the array and it has not
been proposed as a target gene of WT1. Thus the introduction
of BASP1 into K562 cells leads to the repression of a signiﬁcant
proportion of previously identiﬁed WT1 target genes.
We next sought to conﬁrm that the expression of a group of
the above genes was indeed WT1-dependent in K562 cells. V-
K562 or B-K562 cells were transfected with WT1 siRNA or a
control siRNA and, 48 h later, RNA was extracted and cDNA
was prepared. Whole-cell extracts were also immunoblotted with
anti-WT1 antibodies to conﬁrm that WT1 was down-regulated
by the transfection of WT1 siRNA (Figure 2C). qPCR was used
to determine the expression of four of the genes identiﬁed in the
arrayandalsoBaxasacontrol.TransfectionofV-K562cellswith
WT1 siRNA resulted in the down-regulation of amphiregulin,
ETS-1, renin and VDR, consistent with transcriptional activation
of these genes by WT1 in the absence of BASP1. In contrast,
the expression of Bax was not affected by WT1 depletion. As
above, in the B-K562 cells, the expression of the WT1 target
geneswasdown-regulatedwhencomparedwiththeV-K562cells.
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Figure 2 Expression of BASP1 in K562 cells leads to the general down-regulation of WT1 target genes
(A)MicroarrayanalysiswasperformedwithB-K562cellsandV-K562cellsandthedatawereanalysedasdescribedinthetext.Avolcanoplotshowsthat,eventhoughB-K562cellsshowanequivalent
numberofrepressedandactivatedgenes,thevastmajorityofalteredWT1targetgenesarerepressed.Signalwithinthegreyareaindicatessmallchangesbelowthelevelofsigniﬁcance,whereasthered
areashowssigniﬁcantchanges.TheknownWT1targetchangesareindicatedinblue.FulldetailsoftheexpressionchangesobservedinV-K562andB-K562cellsareshowninSupplementaryTableS1(at
http://www.BiochemJ.org/bj/435/bj4350113add.htm).TheprobesetsrepresentingtheWT1targetgenesareshowninSupplementaryTableS2athttp://www.BiochemJ.org/bj/435/bj4350113add.htm.
Sources of the WT1 target genes are cited throughout the text and also include genomic analysis and reviews [2,25,42,43]. (B) qPCR was performed to quantify the expression of the
genes indicated. Results are presented as the expression relative to GAPDH (glyceraldehyde-3-phosphate dehydrogenase) mRNA. Values are means+ −S.D. for three independent experiments.
(C) V-K562 and B-K562 cells were transfected with control siRNA or WT1 siRNA and 48 h later whole-cell extracts or RNA were prepared. Samples were immunoblotted with anti-WT1, anti-BASP1
oranti-β-tubulinantibodies.Theright-handpanelsshowtheexpressionoftheindicatedgenesasdeterminedbyqPCR.Valuesaremeans+ −S.D.forthreeindependentexperiments.(D)V-K562and
B-K562 cells were subject to ChIP analysis with either control, anti-WT1 or anti-BASP1 antibodies. qPCR was used to amplify the WT1-binding sites of the indicated genes or a control region. The
results are expressed as the percentage of bound chromatin compared with input. Values are means+ −S.D. for three independent experiments.
Moreover, consistent with the BASP1-mediated suppression of
WT1 transcription function, the depletion of WT1 in B-K562
cells had little effect on the expression of amphiregulin, ETS-1,
renin or VDR.
Our results so far suggest that BASP1 suppresses the activation
of several WT1 target genes in K562 cells. We next performed
ChIP analysis of V-K562 and B-K562 cells to determine the
occupancy of the WT1-binding site regions of a selection of
the above genes by WT1 and BASP1 (Figure 2D). ChIP was
performedwithcontrol,anti-WT1oranti-BASP1antibodiesusing
fragmented cross-linked chromatin prepared from either V-K562
or B-K562 cells. The WT1-binding regions of the amphiregulin,
ETS-1,reninandVDRgeneswereampliﬁed,alongwithacontrol
genomic region. WT1 was present at the promoter regions of all
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Figure 3 Expression of BASP1 induces an altered PMA-dependent differentiation programme
(A) V-K562 cells or B-K562 cells were treated with 100nM PMA (+) or vehicle (−) and 48h later the cells were photographed. The right-hand panel shows quantiﬁcation of the percentage of
arborized cells. Values are means+ −S.D. for six independent experiments (P <0.005 by Student’s t test). (B) Immunoﬂuorescence of V-K562 and B-K562 cells that had been treated with PMA as in
(A), but for 4 days. Anti-β-tubulin, anti-pol II and anti-BASP1 antibodies were used as indicated. The control is rabbit IgG.
of the genes tested, but not at the control site, in both V-K562
and B-K562 cells. Consistent with the lack of BASP1 expression,
anti-BASP1 antibodies did not signiﬁcantly precipitate the WT1-
binding regions of any of the target genes using fragmented
chromatin prepared from V-K562 cells. However, analysis of the
fragmented chromatin prepared from B-K562 cells revealed that
BASP1 was present within the WT1-binding regions of all of the
target genes tested. Thus BASP1-mediated suppression of WT1
transcriptional activation coincides with the recruitment of
BASP1 to promoter-bound WT1. Taken together, the results
shown in Figure 2 suggest that BASP1 is a negative regulator of
WT1 transcriptional activation at a signiﬁcant proportion of WT1
target genes and acts via recruitment to WT1-bound promoters.
Diversion of K562 cell differentiation by WT1 and BASP1
K562 cells can be induced to differentiate along blood cell
pathway lineages by various agents [31]. We therefore tested
the effect of BASP1 expression on the K562 differentiation
pathway induced by PMA. Treatment of K562 cells with 100 nM
PMA causes the cells to differentiate along the megakaryocyte
lineage. Surprisingly, however, even though the B-K562 cells
appeared morphologically similar to the V-K562 cells before
PMAtreatment,theeffectfollowingPMAtreatmentwasdramatic
(Figure 3A). Whereas PMA treatment of V-K562 cells induced
the formation of megakaryocytes, the PMA-treated B-K562
cells became elongated and formed processes. Quantiﬁcation
of the arborized cells in the differentiated V-K562 and B-
K562 pools is shown on the right-hand side of Figure 3(A).
This quantiﬁcation included any cells that formed a process,
but even the small number observed in the V-K562 cells did
not form processes as elaborate as those observed in the B-
K562 cells. The same effects were observed in a different,
independentlyproduced,stable BASP1-expressingK562cell line
(results not shown and Figure 4). Immunoﬂuorescence was used
to detect β-tubulin in V-K562 and B-K562 cells that had been
treated with PMA for 4 days (Figure 3B). β-Tubulin staining
clearly showed the extent of arborization of the B-K562 cells,
whereas the V-K562 cells maintain the rounded shape typical
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Figure 4 Nuclear BASP1 is required for the altered PMA-dependent differentiation programme of B-K562 cells
(A) New pools of V-K562, B-K562 and B-K562 (K7A:K9A) cells were used to prepare nuclear (N) and cytoplasmic (C) extracts and immunoblotting was performed with the antibodies indicated. (B)
RNA was prepared from V-K562, B-K562 and B-K562 (K7A:K9A) cells and qPCR was performed to quantify the expression of the amphiregulin gene. Data are presented as expression relative to
GAPDH (glyceraldehyde-3-phosphate dehydrogenase) mRNA. Values are means+ −S.D. for three independent experiments. (C) V-K562, B-K562 and B-K562 (K7A:K9A) cells were treated with PMA
as described in Figure 3(A).
of megakaryocytes. BASP1 expression, restricted to the B-K562
cells, shows a nuclear/cytoplasmic distribution comparable with
that observed by us previously in podocyte and Cos-1 cells
[9,13]. Immunoﬂuorescence was also used to detect pol II as
a nuclear marker in differentiated V-K562 and B-K562 cells. It is
evidentfromFigure3thatthePMA-treatedB-K562cellshavenot
differentiated along the megakaryocyte pathway and have instead
gained morphology akin to neuronal cells or ﬁbroblasts.
As mentioned above, BASP1 contains a bipartite NLS at its N-
terminus. We therefore generated a mutant derivative of BASP1
(K7A:K9A) to disrupt the NLS and generated stable K562 cell
lines with either an empty pCDNA expression vector or the same
vector driving expression of either wild-type BASP1 or BASP1
K7A:K9A. Nuclear and cytoplasmic extracts of the cell-line
derivatives were prepared and immunoblotted with anti-BASP1,
anti-WT1 or anti-β-tubulin antibodies (Figure 4A). Mutation of
the BASP1 NLS resulted in a signiﬁcant reduction of nuclear
BASP1. The expression of amphiregulin in each of the cell-
line derivatives was then determined by RNA preparation and
qPCR. The results show that, as before, expression of wild-type
BASP1 resulted in the repression of amphiregulin expression
(Figure 4B). In contrast, the BASP1 mutant derivative K6A:K9A
didnotdriverepressionofamphiregulinexpression.Theseresults
are consistent with the requirement for nuclear localization
of BASP1 to act as a WT1 transcriptional co-suppressor. We
next analysed the effect of PMA on the differentiation of V-
K562, B-K562 or B-K562 (K7A:K9A) cells (Figure 4C). The
results demonstrate that, although wild-type BASP1 diverted
the differentiation programme of K562 cells to an arborized
phenotype, PMA treatment of BASP1 (K7A:K9A) cells did not.
Differentiation of K562 cells has been reported to be
accompaniedbyareductioninWT1expression[13].Wetherefore
determined the fate of WT1 in the V-K562 and B-K562 cells
following treatmentwithPMA.V-K562orB-K562cellswereex-
posed to PMA as described above and whole-cell extracts were
prepared at intervals up to 48 h. Proteins were resolved by
SDS/PAGE, transferred to membrane and immunoblotted with
anti-WT1 antibodies (Figure 5A). Consistent with previous
reports [13], WT1 was down-regulated following treatment of
both the V-K562 and B-K562 cells with PMA, and by 12 h was
almost undetectable. This raised the question of whether or not
thealteredB-K562celldifferentiationprogrammewasdependent
on WT1. To address this, B-K562 cells or V-K562 cells were
transfectedwithWT1siRNAoracontrolsiRNA.Immunoblotting
conﬁrmed that the WT1 siRNA caused a signiﬁcant reduction in
WT1 protein (Figure 5B). Cells transfected with control siRNA
or WT1 siRNA along with a plasmid driving expression of
GFP were then induced to differentiate with PMA for 48 h
followed by imaging to detect the transfected GFP-expressing
cells (Figure 5C). As above, the PMA-treated B-K562 cells
showed a marked difference in their appearance when compared
with the V-K562 cells. However, the transfection of B-K562
cells with WT1 siRNA signiﬁcantly reduced the differentiation-
dependent arborized morphology that is induced by PMA in the
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Figure 5 WT1 is required for the altered PMA-dependent differentiation programme of B-K562 cells
(A)V-K562orB-K562cellsweretreatedwith100nMPMAforthetimesindicatedandthenwhole-cellextractswerepreparedandsubjectedtoimmunoblottingwithanti-WT1 antibodies.(B)V-K562
and B-K562 cells were transfected with either control or WT1 siRNA. At 24h later, whole-cell extracts were prepared and immunoblotted with the antibodies indicated. (C) V-K562 or B-K562 cells
were transfected as described in (B) along with a vector driving expression of GFP, and 24h later were treated with 100nM PMA or vehicle control. At 48h later, the cells were imaged. Quantiﬁcation
of the arborized cells is shown in the lower panel. Values are means+ −S.D. for six experiments (P <0.05 by Student’s t test).
B-K562 cells. Quantiﬁcation of the arborized cells is shown
below. Thus WT1 expression is required for the altered
differentiationprogrammeofB-K562cellsthatoccursinresponse
to PMA treatment.
The regulation of gene expression by WT1 and BASP1 in
differentiating K562 cells
We next explored the gene-regulatory events that result
in the WT1/BASP1 reprogramming of the PMA-dependent
differentiation pathway in K562 cells. Arrays were performed
with RNA derived from vehicle-treated V-K562 or B-K562
cells, and also the same cells treated with PMA (independently
preparedtriplicates).Alistofsigniﬁcantgeneexpressionchanges
was generated by ﬁltering for the ANOVA interaction (q-
value<0.05) and fold change between differentiated B-K562
compared with V-K562 >+ − 2. This gave 788 probesets, which
were grouped into ﬁve clusters based on their expression
proﬁles over the four conditions as shown in Figure 6(A) (full
details are in Supplementary Table S3 at http://www.BiochemJ.
org/bj/435/bj4350113add.htm). The changes in gene expression
fall into ﬁve clusters (A–E). Cluster E genes are highly induced
in the PMA-treated V-K562 cells, but not by PMA-treatment of
B-K562 cells. This group includes ITGA2 (integrin α2, CD49B),
ITGA2B (integrin α2b, CD41), ITGB3 (integrin β3, CD61),
PPBP(pro-plateletbasicprotein),CD2226,CD84,Arhgap9(Rho
GTPase-activating protein 9) and DAB2, all of which are well-
characterizedgenesthatareinvolvedinthedifferentiationofK562
cells along a megakaryocyte programme [31,32]. In Figure 6(B),
qPCR validation of the array data for the megakaryocyte marker
genes ITGA2, DAB2, ITGA2B and ITGB3 is shown, conﬁrming
theinductionofthesegenesinPMA-treatedV-K562cells,butnot
PMA-treated B-K562 cells. Thus the expression data can explain
why the B-K562 cells do not differentiate into megakaryocyte
cells upon exposure to PMA.
Cluster A contains genes that are up-regulated in B-K562, but
signiﬁcantly less so in V-K562 cells following PMA treatment.
These genes include ENC1, Pak1 (p21-activated kinase 1) and
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Figure 6 Differentiation-dependent regulation of gene expression in V-K562 and B-K562 cells
(A) Arrays were performed with RNA derived from vehicle-treated V-K562 or B-K562 cells and also the same cells treated with PMA. The data were analysed as described in the text. V,
V-K562 cells; B, B-K562 cells. A colour-coded key of expression level is shown below the panel. Five distinct clusters of genes (A–E) are indicated on the right. Supplementary Table S3 (at
http://www.BiochemJ.org/bj/435/bj4350113add.htm) shows the genes associated with each cluster. (B) qPCR analysis of selected genes from clusters E (top panels) and A (bottom panels). Values
are means+ −S.D for three independent experiments. (C) Immunoﬂuorescence was performed with V-K562 and B-K562 cells that had been treated with PMA and allowed to differentiate for 4 days.
Antibodies are indicated above the panels. The control is rabbit IgG.
Nidogen2, which have been shown to play a role in axon growth
(qPCR for ENC1 shown in Figure 6B, lower panel; [33–35]).
In addition, cluster A contains synapsin I, P2X5 and MAOA
(monoamine oxidase A; qPCR shown in Figure 6B), which all
play a central role in synapse function [36,37]. Figure 6(C) shows
immunoﬂuorescence with anti-β-tubulin (cytoplasm marker),
anti-BASP1, anti-DAB2 (megakaryocyte marker), anti-ENC1
and anti-P2X5 antibodies, conﬁrming that the changes in mRNA
are accompanied by changes in protein. Speciﬁcally, the results
show that DAB2 expression is restricted to the differentiated V-
K562 cells, whereas ENC1 and P2X5 expression are elevated in
the differentiated B-K562 cells. Thus the expression of BASP1 in
K562 cells diverts the PMA-induced differentiation programme
away from the megakaryocyte pathway, and instead leads to a
morphological appearance akin to neuronal cells. The altered
differentiation pathway of B-K562 cells requires the expression
of WT1, which is accompanied by the suppression of genes
that specify the megakaryocyte and, furthermore, leads to the
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Figure 7 PMA-differentiated B-K562 cells are responsive to the neurotransmitter ATP
(A) A 30 s application of 10mM ATP elicited a large increase in cytosolic calcium in B-K562 cells that slowly returned to baseline levels as ATP was washed out. (B) A comparable ATP application
in V-K562 cells did not affect baseline calcium levels. Application of 10mM CPA, a reversible SERCA pump inhibitor, illustrates that it was possible to evoke a measurable change in cytosolic
calcium in these cells. (C) Analysis of ATP responsiveness in B-K562 and V-K562 cells on days 4 and 7 after PMA-induced differentiation in culture found that B-K562 cells were signiﬁcantly more
responsive to ATP than the V-K562 cells on both days 4 (B-K562, n=54; V-K562, n=16) and 7 (B-K562, n=20; V-K562, n=39). **P <0.005.
induction of several genes involved in axon growth and synapse
function.
Neuronal properties of B-K562 cells
The neurotransmitter receptor P2X5 was signiﬁcantly up-
regulated in B-K562 cells following PMA treatment (Figure 6B).
P2X5 is a ligand-gated purinergic receptor that responds
to extracellular ATP and is found in both neurons and
muscle cells [36]. Therefore we next determined whether the
B-K562 cells possess the capacity to elicit a response to ATP.
V-K562 or B-K562 cells were induced to differentiate by
treatment with PMA for 4 days. ATP (10 mM) was then applied
to the cells and calcium inﬂux was measured by ﬂuorescence
imaging. The treatment of differentiated B-K562 cells with ATP
caused a rapid increase in cytosolic calcium that slowly returned
to baseline calcium levels in 87% of cells tested (example shown
in Figure 7A, upper panel). The ATP response in B-K562 cells
was abolished when external calcium was removed, indicating
that the calcium signal was due to an inﬂux from the external
environment(resultsnotshown).ExperimentsusingB-K562cells
that had been treated with PMA for 7 days yielded similar results
(shown graphically in Figure 7B). In contrast, similar treatment
of the differentiated V-K562 cells revealed that only 10% of
the cells were sensitive to ATP, even when we increased the
ATP concentration to 500 mM (example shown in Figure 7A,
lower panel, and quantiﬁcation is shown in Figure 7B). However,
application of the reversible SERCA (sarcoplasmic/endoplasmic
reticulum Ca
2+-ATPase) inhibitor CPA elicited a response,
conﬁrming that the V-K562 cells are viable and are speciﬁcally
unresponsivetoATP(Figure7A,lowerpanel).Statisticalanalysis
ofthenumberofATP-sensitivecellsfoundthatB-K562cellswere
signiﬁcantly more responsive to ATP compared with the V-K562
cells (P<0.005). Thus the expression of synaptic proteins in the
PMA-induced B-K562 cells is accompanied by the endowment
of the cells with the capacity to respond to the neurotransmitter
ATP.
Speciﬁcity of differentiation reprogramming of B-K562 cells
K562 cells are situated at the common progenitor stage of the
megakaryocyte and erythroid lineages of haemopoietic stem
cell differentiation [31]. Whereas PMA induces K562 cells to
differentiate along a megakaryocyte programme, haemin can
induce K562 cells to differentiate along an erythroid programme.
We therefore treated the V-K562 and B-K562 cells with haemin
or PMA, and 48 h later, imaged the cells under phase microscopy
(Figure 8A). As before, PMA treatment induced the arborization
oftheB-K562cells,butnottheV-K562cells.However,following
treatment with haemin, the morphology of the B-K562 cells was
similar to that of the V-K562 cells. To conﬁrm that the induction
of megakaryocyte and erythrocyte differentiation was successful,
RNA was prepared and cDNA was derived, then qPCR was
performed to analyse the expression of ITGA2 (megakaryocyte
marker), ENC1 (induced by PMA in B-K562 cells and involved
in axon growth) and γ-globin (a standard marker for erythroid
c   The Authors Journal compilation c   2011 Biochemical Society © 2010 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.WT1/BASP1 in gene regulation and differentiation 123
Figure 8 BASP1 speciﬁcally diverts the megakaryocyte pathway of K562 cell differentiation
(A) V-K562 and B-K562 cells were mock-treated or treated with 100nM PMA or 0.5 mM haemin, and 48h later the cells were imaged using phase microscopy. (B)A si n( A), except that RNA was
prepared and analysed by qPCR for the expression of the genes indicated. Values are means+ −S.D. for three independent experiments.
differentiation). As above, ITGA2 was speciﬁcally induced by
PMA only in the V-K562 cells, and ENC1 was induced by PMA
only in the B-K562 cells (Figure 8B). The marker for erythroid
differentiation, γ-globin, was induced only by haemin, but this
was observed in both the V-K562 and B-K562 cells. These results
suggest that the erythroid differentiation pathway of the K562
cells is, at least in part, intact in the B-K562 cells. Thus the
expression of BASP1 speciﬁcally results in the reprogramming
of the megakaryocyte differentiation pathway of K562 cells that
is induced by PMA.
DISCUSSION
In the present study we have demonstrated that the stable
expression of BASP1 in K562 cells leads to the down-
regulation of a signiﬁcant proportion of WT1-dependent target
genes. ChIP analysis conﬁrmed that the suppression of WT1-
mediated transcriptional activation by BASP1 coincides with
the recruitment of BASP1 to WT1-dependent promoters. Taken
together, the results of the present study suggest that BASP1 is a
general regulator of WT1 that acts to suppress the transcriptional
activation function of WT1. BASP1 expression in K562 cells
also led to the activation and repression of several other genes,
the majority of which are unlikely to be direct targets of WT1.
Although this will include indirect effects, it is also possible that
BASP1 may act through other transcription factors either as a
co-repressor or co-activator.
PMA-induced differentiation of K562 cells into megakaryo-
cytes was blocked by the expression of BASP1. Indeed, several
markers of megakaryocyte differentiation failed to up-regulate in
response to PMA, presumably due to the altered gene expression
proﬁle that was established by the expression of BASP1. Instead,
the K562 cells that express BASP1 gained a neuronal-like
morphologyfollowingtreatmentwithPMAthatwasaccompanied
by the induction of several genes that are involved in axon
extensionandsynapsefunction.ThePMA-induceddifferentiation
of K562 cells to megakaryocytes is well established and has been
studied for several years. One study has reported that K562 cells
can differentiate, albeit at a low efﬁciency, to antigen-presenting
dendritic cells. However, none of the dendritic cell markers (e.g.
MHC class I and class II, interleukin-12, CD86 and CD40)
were induced in the B-K562 cells, suggesting that this particular
pathway is not induced by WT1 and BASP1 [38]. The PMA-
treatedB-K562cellsexhibitedcalciuminﬂuxwhenexposedtothe
neurotransmitter ATP, suggesting a gain-of-function consistent
with an excitable cell. To our knowledge, this is the ﬁrst report
that K562 cells have been differentiated into anything other than
a blood cell.
BASP1 can induce arborization of PC12E2 neuronal cells or
primary hippocampal neurons [39]. Moreover, WT1 has been
shown to be required for the neuronal differentiation of Y-79
retinoblastoma cells in culture [40], formation of the retinal
ganglia and olfactory epithelia [4,5], and is expressed in several
other neuronal cells [6]. However, the results of the present
study demonstrate that WT1 and BASP1 can induce neuronal-
like morphology and physiological properties in cells that are
not originally from a neuronal lineage. Thus WT1 and BASP1
together can reprogramme the differentiation potential of K562
cells.
WT1 and BASP1 are co-expressed in the podocyte cells of
the developing and adult kidney, which form processes that
surround the capillary network of the glomerulus and provide
a ﬁltration barrier [9]. Our previous studies suggested that
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WT1 and BASP1 co-operate in the changes in gene regulation
that occur during the differentiation of podocytes in vitro [13].
It is therefore interesting to note that parallels between the
formation of processes in podocytes and neurons have been
drawn,particularlyregardingtheformationofcellularextensions,
which are microtubule-rich with actin-based projections [41].
Moreover, several genes involved in intracellular trafﬁcking,
signaltransductionandcytoskeletalcomponentsareco-ordinately
expressed in both cell types. It is therefore possible that WT1 and
BASP1 play an important role in establishing the transcription
networks associated with cellular arborization in podocytes and
some neuronal cells. In contrast with the events in podocytes,
however, the differentiation of K562 cells is accompanied by a
reduction in WT1 expression. This suggests that the neuronal
characteristics that we report in the present paper require the
transient function of WT1, and that WT1 is probably not needed
for the maintenance of the differentiated phenotype.
ItisinterestingtonotethatBASP1expressiondoesnotappearto
affect the haemin-induced differentiation of K562 cells along the
erythrocyte pathway, at least morphologically or in the induction
of γ-globin expression. Thus WT1 and BASP1 expression do
not ﬁx the destiny of K562 cells to a neuronal-like lineage.
However, the alterations set the stage for further changes that
are induced by PMA, but require the prior modiﬁcations that have
been induced by WT1 and BASP1. The precise chain of events
that leads from WT1/BASP1 regulation of transcription to the
reprogramming of K562 differentiation induced by PMA is likely
to be complex. Indeed several cell types, including others that are
blood-cell-derived, express WT1 and BASP1. We suggest that
the action of WT1 and BASP1 on speciﬁc target genes results
in changes in the cellular milieu that, under speciﬁc conditions,
can lead to arborization. In summary, the results of the present
study suggest that WT1 and BASP1 can co-operatively act at
fundamental step(s) in determining the differentiation pathway.
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